Subscribe to RSS

DOI: 10.1055/s-0045-1813678
Consideration of Radioactive Iodine Therapy in a Graves' Disease Patient with Secondary Psychosis: A Case Report
Authors
Abstract
Psychosis is a rare but recognized neuropsychiatric complication of hyperthyroidism, most commonly associated with Graves' disease. Although anxiety and mood disturbances are more frequent, acute psychosis has been reported in approximately 1% of cases.
We report the case of a 30-year-old man with a 1-year history of Graves' disease who developed acute psychotic symptoms, including hallucinations and disorganized behavior. Laboratory findings revealed severe thyrotoxicosis with a suppressed thyroid-stimulating hormone and markedly elevated free T4. Thyroid scintigraphy using technetium-99m pertechnetate demonstrated diffuse increased uptake consistent with toxic diffuse goiter. The patient with severe thyrotoxicosis was initially managed with methimazole, propranolol, and psychiatric medications. Although the scheduled 1-week follow-up was missed, he returned at 4 weeks while continuing his prescribed therapy. At that visit, repeat thyroid function tests were obtained and psychiatric care was maintained. Subsequently, radioactive iodine (RAI) therapy at a fixed dose of 370 MBq (10 mCi) was administered after a short withdrawal of antithyroid drugs. One month posttreatment, both thyroid function and psychiatric symptoms improved significantly, allowing for discontinuation of antipsychotics. At 3 months, he became hypothyroid and was started on levothyroxine replacement.
This case highlights the importance of a multidisciplinary approach in managing patients with coexisting psychiatric conditions. Psychosis secondary to hyperthyroidism may mimic primary psychiatric disorders, potentially delaying diagnosis. Stabilizing psychiatric symptoms prior to definitive therapy and ensuring close psychiatric follow-up are essential to achieving optimal clinical outcomes. Radioiodine remains a safe and effective treatment for Graves' disease, even in patients with neuropsychiatric complications.
The psychotic symptoms in this case are caused by hyperthyroidism. RAI therapy can effectively and safely treat hyperthyroidism in Graves' disease patients with secondary psychosis.
Keywords
Graves' disease - hyperthyroid - nuclear medicine - radioactive iodine - RAI - secondary psychosisPublication History
Article published online:
18 December 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Davies TF, Andersen S, Latif R. et al. Graves' disease. Nat Rev Dis Primers 2020; 6 (01) 52
- 2 Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95 (06) 2715-2726
- 3 Girgis CM, Champion BL, Wall JR. Current concepts in graves' disease. Ther Adv Endocrinol Metab 2011; 2 (03) 135-144
- 4 Desai D, Zahedpour Anaraki S, Reddy N, Epstein E, Tabatabaie V. Thyroid storm presenting as psychosis. J Investig Med High Impact Case Rep 2018; 6: 2324709618777014
- 5 Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008; 358 (24) 2594-2605
- 6 Brownlie BEW, Rae AM, Walshe JWB, Wells JE. Psychoses associated with thyrotoxicosis - 'thyrotoxic psychosis.' A report of 18 cases, with statistical analysis of incidence. Eur J Endocrinol 2000; 142 (05) 438-444
- 7 Graves RJ. Newly observed affection of the thyroid gland in females. Lond Med Surg J. 1835; 7: 516-517
- 8 Dunlap HF, Moersch FP. Psychic manifestations associated with hyperthyroidism. Am J Psychiatry 1935; 91: 1215-1236
- 9 Bunevicius R, Prange Jr AJ. Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options. CNS Drugs 2006; 20 (11) 897-909
- 10 Klein I, Levey GS. New perspectives on thyroid hormone, catecholamines, and the heart. Am J Med 1984; 76 (02) 167-172
- 11 Mason GA, Bondy SC, Nemeroff CB, Walker CH, Prange Jr AJ. The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. Psychoneuroendocrinology 1987; 12 (04) 261-270
- 12 Adediran KI, Alapati D, Rasimas JJ. Delusional psychosis in Graves' disease. Prim Care Companion CNS Disord 2018; 20 (01) 17l02145
- 13 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26 (10) 1343-1421
- 14 Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003; 88 (03) 978-983
- 15 Anaissie E, Tohmé JF. Reserpine in propranolol-resistant thyroid storm. Arch Intern Med 1985; 145 (12) 2248-2249
- 16 Kathol RG, Turner R, Delahunt J. Depression and anxiety associated with hyperthyroidism: response to antithyroid therapy. Psychosomatics 1986; 27 (07) 501-505
- 17 Trzepacz PT, McCue M, Klein I, Greenhouse J, Levey GS, Levey EJ. Psychiatric and neuropsychological response to propranolol in Graves' disease. Biol Psychiatry 1988; 23 (07) 678-688
- 18 Hyams C, Joshi P, Foster P, Katz J. Acute psychosis caused by hypothyroidism following radioactive iodine treatment of Graves' disease. JRSM Short Rep 2013; 4 (04) 26
- 19 Nemeroff CB, Putnam JS. β-Adrenergic receptor antagonists. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 2722-2727
- 20 Hoffman BB. Catecholamine sympathomimetic drugs and adrenergic receptor antagonists. In: Hardman JG, Limbird LL, Gilman AG. eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: 253-254

